Intervacc AB (publ) acquires Nordvacc

Stockholm, March 24, 2014
Press release

Intervacc AB (publ) acquires Nordvacc Läkemedel AB and creates a leading player within the veterinary pharmaceutical market in Scandinavia and the Baltic countries.

By the acquisition, Intervacc complements its on-going research and in-house developed vaccine with a well-established distributor of veterinary pharmaceuticals and vaccines.

Nordvacc Läkemedel was founded in 1988 by Rune Bergman and Kenneth Janzon with its head quarters in Stockholm with business offices in Denmark, Finland, and the Netherlands and a subsidiary in Latvia. Totally, Nordvacc has sold more than 150 million doses of vaccine and has the distribution rights to 25 products in 8 countries. Nordvacc also owns Mybac-Vettech, which performs clinical microbiological analyses. During 2013 Nordvacc had a turn-over of SEK 95 million with good profitability and had 12-14 employees.

"Intervacc's vaccine Strangvac®, against strangles in the horse, will at the beginning of next year go into the registration phase and we will then start preparations for the market launch. Both parties therefore consider that the timing is right for the merger of the companies. Nordvacc today has a strong market presence in Northern Europe providing Intervacc access to distribution channels in a number of key markets. Nordvacc's strong cash flow will build value by securing financing for the development of further products based on the same technology platform that forms the basis for the development of Strangvac®" says Jan-Ingmar Flock CEO of Intervacc.

"The plans for a merger have long been discussed due to the complementing activities and based on the fact that Nordvacc has the rights to Intervacc's vaccine candidate on some geographical markets" says Rune Bergman CEO and co-founder of Nordvacc.

Nordvacc and its subsidiaries will become consolidated into the new group of companies from January 1st 2014. Nordvacc will become part of a group of companies where Intervacc is the mother company. Nordvacc will be run unaltered in its present form also after the merger. Main owner of the new group of companies will be Nordvacc Läkemedel Holding, which is controlled by the founders of Nordvacc. Financing of the acquisition will be done by a combination of external credits and own capital.

For further information, please contact
Jan-Ingmar Flock, CEO
jan-ingmar.flock@intervacc.com
Tel +46-(0)8-120 10 602 or -46-(0)73-334 14 11

About Intervacc
Intervacc AB (publ) is a company in the biotechnology sector. Its main areas are to develop modern subcomponent vaccines against economically important bacterial infections, mainly within animal health. The company's vaccine candidates are based on several years of research at

Karolinska Institutet and the Swedish University of Agricultural Sciences, which has created the platform on which the company has its research and development activities based.

Date Created
2014-03-24